MAPK pathway mutations, such as BRAF and RAS, increase the likelihood of PTC occurrence, evolution, and prognosis, while the PI3K-AKT pathway leads to FTC through mutations like RAS, PIK3CA, and AKT1. Here, AKT1 is linked to thyroid cancer, nonmedullary, 2.